Showing results (381-390 of 431) with videos related to
Sort By:
Pageof 44
Journal of the National Cancer Institute|July 16, 2026
Recurrence Score® gene group components and outcomes in the RxPONDER trial (SWOG S1007)Yara Abdou, Jess Hoag, William E Barlow, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2020
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline UpdateKimberly H Allison, M Elizabeth H Hammond, Mitchell Dowsett, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2025
Novel Postneoadjuvant Prognostic Breast Cancer Staging SystemDavid J Winchester, Lavisha Singh, Stephen B Edge, et al.Breast Cancer Research and Treatment|July 19, 2011
Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221)Lara E Sucheston, Hua Zhao, Song Yao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2020
Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORxLynne I Wagner, Robert J Gray, Joseph A Sparano, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateAntonio C Wolff, M Elizabeth H Hammond, David G Hicks, et al.Archives of Pathology & Laboratory Medicine|January 14, 2020
Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline UpdateKimberly H Allison, M Elizabeth H Hammond, Mitchell Dowsett, et al.JAMA Oncology|December 11, 2025
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical TrialIrene M Kang, Jamie K Forschmiedt, Michelle M Loch, et al.Archives of Pathology & Laboratory Medicine|October 9, 2013
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateAntonio C Wolff, M Elizabeth H Hammond, David G Hicks, et al.Journal of the National Cancer Institute|December 28, 2020
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working GroupTorsten O Nielsen, Samuel C Y Leung, David L Rimm, et al.Pageof 44